Corden Pharma GmbH
Corden Pharma GmbH, a leading contract development and manufacturing organisation (CDMO), is headquartered in Germany and operates across multiple regions, including Europe and North America. Founded in 2006, the company has established itself in the pharmaceutical and biotechnology sectors, specialising in the development and production of complex drug formulations, including injectables and oral solid dosage forms. Corden Pharma is renowned for its comprehensive range of services, from early-stage development to commercial manufacturing, with a strong emphasis on quality and regulatory compliance. The company’s unique capabilities in active pharmaceutical ingredient (API) production and advanced drug delivery systems position it as a trusted partner for clients seeking innovative solutions. With a commitment to excellence, Corden Pharma has achieved significant milestones, solidifying its market position as a preferred CDMO for global pharmaceutical companies.
DitchCarbon Score
How does Corden Pharma GmbH's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Chemicals industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Corden Pharma GmbH's score of 23 is higher than 92% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Corden Pharma GmbH's reported carbon emissions
Corden Pharma GmbH, headquartered in Germany, has made significant commitments towards reducing its carbon emissions, although specific emissions data for the most recent year is not available. The company is committed to achieving net-zero emissions across all scopes by 2050, with a starting point in 2023. This long-term target aligns with the Science Based Targets initiative (SBTi), indicating a robust commitment to climate action within the pharmaceuticals, biotechnology, and life sciences sector. Corden Pharma is a member of the Business Ambition for 1.5°C initiative, demonstrating its dedication to limiting global warming to 1.5°C above pre-industrial levels. The company has been proactive in its climate strategy, having committed to net-zero emissions and actively participating in industry-wide efforts to mitigate climate change. While specific reduction targets or absolute emissions figures are not provided, Corden Pharma's long-term vision reflects a comprehensive approach to sustainability and environmental responsibility. The company's initiatives are crucial in the context of the pharmaceutical industry's growing focus on reducing its carbon footprint and enhancing sustainability practices.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Corden Pharma GmbH is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
